Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
Suzhou Connect Biopharma is developing a proprietary technology to enable rapid and efficient selection of human antibodies against GPCR targets. This technology exploits the unique structural features (hot spots) of a GPCR subfamily that are critically involved in autoimmune diseases and cancer, particularly malignancy of the immune system. The technology will allow for high-throughput screening of human antibody library for discovery of high affinity binders and subsequent identification of antibody drug candidates with high functionalities. We will use this technology platform to identify therapeutics antibody drug candidates as well as forming discovery partnership with other biopharmaceutical companies.
Copyright: Suzhou Connect Biopharmaceuticals, Ltd.